Repaglinide

From WikiMD's WELLNESSPEDIA

Repaglinide
File:Repaglinide ball-and-stick.png
Repaglinide ball-and-stick model

Information about Repaglinide[edit]

Repaglinide is a benzoic acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabetes.

Liver safety of Repaglinide[edit]

Repaglinide has been linked to rare instances of clinically apparent acute liver injury.

Mechanism of action of Repaglinide[edit]

Repaglinide (re pag' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a benzoid acid derivative that, like the sulfonylureas, stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Repaglinide has been shown to reduce the postprandial increase in glucose in patients with type 2 diabetes and improve glycemic control. Repaglinide

FDA approval information for Repaglinide[edit]

Repaglinide was approved for use in the United States in 1997. The current indications are for management of type 2 diabetes used in combination with diet and exercise, with or without other oral hypoglycemic agents.

Brand name for Repaglinide[edit]

Repaglinide is available generically and under the brand name Prandin in tablets of 0.5, 1 and 2 mg.

Dosage and administration for Repaglinide[edit]

The typical initial dose in adults is 0.5 mg three times daily before meals, with a gradual increase to a maximum of 16 mg daily.

Side effects of Repaglinide[edit]

Side effects of repaglinide include diarrhea, nausea, gastrointestinal upset, hypoglycemia, headache, dizziness, arthralgia and rash. Antidiabetics


Template:Ion channel modulators